Alan L Ho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5690942/publications.pdf

Version: 2024-02-01

65 papers	8,994 citations	136950 32 h-index	110387 64 g-index
65 all docs	65 docs citations	65 times ranked	14698 citing authors

#	Article	IF	Citations
1	Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic Features. Head and Neck Pathology, 2022, 16, 612-620.	2.6	6
2	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. Molecular Cancer Research, 2022, 20, 45-55.	3.4	13
3	Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid, 2022, 32, 273-282.	4.5	30
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
5	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	2.0	41
6	ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. Modern Pathology, 2022, 35, 895-902.	5.5	7
7	Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirusâ€“related malignancies. Oral Oncology, 2022, 128, 105806.	1.5	4
8	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). Journal of Clinical Oncology, 2022, 40, 1870-1878.	1.6	29
9	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. Thyroid, 2022, 32, 799-806.	4.5	4
10	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. Cancer Discovery, 2021, 11, 1158-1175.	9.4	57
11	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 30-37.	1.6	239
12	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	6.3	98
13	Any day, split halfway: Flexibility in scheduling highâ€dose cisplatinâ€”A large retrospective review from a highâ€volume cancer center. International Journal of Cancer, 2021, 149, 139-148.	5.1	1
14	Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11â€year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts. Head and Neck, 2021, 43, 2497-2509.	2.0	2
15	Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. Endocrine-Related Cancer, 2021, 28, 391-402.	3.1	10
16	Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations. Journal of Clinical Oncology, 2021, 39, 1856-1864.	1.6	100
17	Therapeutic strategies for systemic therapies of human papillomavirusâ€related oropharyngeal cancer. Journal of Surgical Oncology, 2021, 124, 952-961.	1.7	1
18	Androgen Receptor Pathway in Salivary Gland Cancer. Journal of Clinical Oncology, 2021, 39, 4069-4072.	1.6	5

#	Article	IF	Citations
19	Dynamic contrastâ€enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. NMR in Biomedicine, 2020, 33, e4166.	2.8	19
20	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 106, 564-570.	0.8	51
21	Tipifarnib in recurrent, metastatic HRASâ€mutant salivary gland cancer. Cancer, 2020, 126, 3972-3981.	4.1	34
22	The 3 Bs of cancer care amid the COVIDâ€19 pandemic crisis: â€œBe safe, be smart, be kindâ€â€”A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. Cancer, 2020, 126, 4092-4104.	4.1	24
23	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Clinical Cancer Research, 2020, 26, 2859-2870.	7.0	75
24	Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer, 2020, 126, 2153-2162.	4.1	38
25	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	9.4	149
26	Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis. Tomography, 2020, 6, 129-138.	1.8	14
27	The immune microenvironment and expression of PDâ€L1, PDâ€1, PRAME and MHC I in salivary duct carcinoma. Histopathology, 2019, 75, 672-682.	2.9	43
28	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. Cancer, 2019, 125, 2984-2990.	4.1	4
29	Sex disparities in salivary malignancies: Does female sex impact oncological outcome?. Oral Oncology, 2019, 94, 86-92.	1.5	7
30	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine, 2019, 25, 767-775.	30.7	282
31	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human Pathology, 2019, 88, 66-77.	2.0	38
32	Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1417-1428.	3.6	165
33	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
34	Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. , 2019, , .		7
35	Challenges and Opportunities for Developing New Therapeutics for Salivary Gland Cancers. Journal of Oncology Practice, 2018, 14, 109-110.	2.5	3
36	Longâ€term quality of life in older patients with HPVâ€related oropharyngeal cancer. Head and Neck, 2018, 40, 2321-2328.	2.0	6

#	Article	IF	Citations
37	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 2018, 78, 4642-4657.	0.9	60
38	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs, 2017, 35, 742-750.	2.6	10
39	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4119-4126.	7.0	17
40	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nature Communications, 2017, 8, 1197.	12.8	77
41	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodineâ€refractory thyroid cancer. Cancer, 2017, 123, 4114-4121.	4.1	59
42	Clinical and Morphologic Characteristics of MEK Inhibitorâ€“Associated Retinopathy. Ophthalmology, 2017, 124, 1788-1798.	5.2	95
43	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	7.1	191
44	Androgen Receptor Signaling in Salivary Gland Cancer. Cancers, 2017, 9, 17.	3.7	69
45	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
46	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
47	Unmet needs for patients with salivary gland cancer. Oral Oncology, 2016, 60, 142-145.	1.5	5
48	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. Cancers of the Head & Neck, 2016, 1, 4.	6.2	19
49	Novel Approaches to Thyroid Cancer Treatment and Response Assessment. Seminars in Nuclear Medicine, 2016, 46, 109-118.	4.6	30
50	Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. Journal of Clinical Investigation, 2016, 126, 4119-4124.	8.2	102
51	Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Human Pathology, 2015, 46, 26-33.	2.0	103
52	Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy. Journal of Skin Cancer, 2014, 2014, 1-7.	1.2	37
53	A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. Investigational New Drugs, 2014, 32, 549-554.	2.6	5
54	Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapyâ€™s local control superior?. Radiology and Oncology, 2014, 48, 56-61.	1.7	30

#	Article	IF	Citations
55	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. Journal of Radiation Oncology, 2013, 2, 285-291.	0.7	3
56	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2013, 14, 371-382.	10.7	171
57	Moving toward a better understanding of radioiodine action. Endocrine, 2013, 44, 553-554.	2.3	3
58	Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. New England Journal of Medicine, 2013, 368, 623-632.	27.0	692
59	PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma. Cancer Research, 2012, 72, 4515-4525.	0.9	68
60	Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype. PLoS ONE, 2012, 7, e40439.	2.5	63
61	Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncology, The, 2011, 12, 815-824.	10.7	311
62	Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. Radiotherapy and Oncology, 2011, 101, 425-430.	0.6	88
63	Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer. Clinical Advances in Hematology and Oncology, 2011, 9, 32-41.	0.3	7
64	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
65	Aurora B Kinase Regulates the Postmitotic Endoreduplication Checkpoint via Phosphorylation of the Retinoblastoma Protein at Serine 780. Molecular Biology of the Cell, 2009, 20, 2218-2228.	2.1	87